Are nanoparticles the key to more effective eye drops?

Article

Researchers at the University of Reading, UK, report that they have discovered a potential way of making eye drops more effective.

Researchers at the University of Reading, UK, report that they have discovered a potential way of making eye drops more effective.

The researchers report in Molecular Pharmaceutics that they have developed nanoparticles that could attach to the cornea and resist being washed out by tear fluid for an extended period of time. If these nanoparticles are loaded with a drug, the researchers say, their longer attachment to the cornea would ensure more medicine penetrates the eye and improves drop treatment.

Professor Vitaliy Khutoryanskiy, from the University of Reading's School of Pharmacy, said, "Treating eye disorders is a challenging task. Our corneas allow us to see and serve as a barrier that protects our eyes from microbial and chemical intervention. Unfortunately this barrier hinders the effectiveness of eye drops. Many medicines administered to the eye are inefficient, as they often cannot penetrate the cornea barrier. Only the very small molecules in eye drops can penetrate [a] healthy cornea.

"Our research in bovine models showed that penetration of small drug molecules could be improved by adding enhancers such as cyclodextrins," Prof. Khutoryanskiy added. "This means eye drops have the potential to be a more effective, and a more comfortable, future treatment for disorders such as age-related macular degeneration."

In the same paper, the researchers revealed insights into how the structure of the cornea prevents various small and large molecules, as well as nanoparticles, from entering into the eye, and examined the effects any damage to the eye would have in allowing these materials to enter the body.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.